Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Medullary thyroid carcinoma (MTC) is a rare, aggressive thyroid cancer originating from parafollicular cells.
• MTC typically exhibits a low mutational burden, with common oncogenic events involving RET or RAS gene mutations.
• Current treatments like multitarget kinase inhibitors (MKIs) face challenges including adverse events, variable efficacy, and resistance.

Purpose of the Study:

• To review MTC signaling pathways.
• To discuss current and emerging treatment options for advanced MTC.
• To explore the potential of personalized medicine in MTC management.

Main Methods:

• Literature review of MTC signaling pathways.
• Analysis of approved and investigational therapies for MTC.
• Discussion of personalized medicine approaches.

Main Results:

• MTC is characterized by specific genetic alterations, primarily in RET and RAS pathways.
• Approved MKIs like vandetanib and cabozantinib offer treatment but have limitations.
• There is a clear need for more effective and specific therapies, such as novel RET-specific TKIs.

Conclusions:

• Understanding MTC signaling is crucial for targeted therapy development.
• Newer RET-specific TKIs hold promise for improved efficacy and reduced toxicity in MTC.
• Personalized medicine strategies are essential for optimizing MTC treatment outcomes.